—
C+
C+ The full Closelook — membership. Open the C+ overview

Bausch Health Companies Inc (BHC.TO) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Bausch Health Companies Inc

BHC.TO in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Bausch Health is a diversified specialty pharmaceutical and medical device company operating through five segments: Salix, International, Solta Medical, Diversified and Bausch + Lomb. It develops and sells products across gastroenterology, hepatology, neurology, dermatology, generics, dentistry, over-the-counter care, aesthetic devices and eye health, across many countries. It is headquartered in Laval, Canada, and was formerly known as Valeant Pharmaceuticals International.
Where it sits in the stack
Bausch Health carries no seat in our index, so it sits within our broader healthcare universe, in the specialty and generic drugmakers sleeve rather than the AI build-out stack. Its business runs on prescription and device sales rather than compute infrastructure, so it stands outside the layers our diary tracks for chip and data-centre demand.
Who it is priced against
Bausch Health is best read against other specialty and generic drugmakers with multiple therapeutic lines, a group that includes Teva Pharmaceutical as a name the market often names alongside it.
Why Closelook tracks it
Bausch Health holds no seat in our index and carries no score yet, so the diary follows it only through its own chart readings rather than through index quotes.
What the diary watches
Whether the shares extend their move further below both the 50-day and 200-day averages, since they already sit under each and well off their 52-week high.

Bausch Health Companies Inc (BHC.TO) trades on the TO exchange in Canada, classified under Healthcare.

The Closelook company score reads 54/100 composite (momentum 50, quality 70, valuation 83) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for BHC.TO, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Drug Manufacturers - Specialty & Generic · 8 names with week and year-to-date

Peer group

Drug Manufacturers - Specialty & Generic

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against BHC.TO on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return no distribution in twelve months

Dividends and capital return

What BHC.TO pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count +1.9% in FY2025 216 m CAD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 50/100 · S&P 500 fund at 49, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-18
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 97th percentile of the window, +4.9% over 20 sessions. Factor regime → 2026-09-18
  • Sovereign pressure Index 0.07 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-18

FAQ · from the current data · as of 2026-09-19

Quick answers

What is Bausch Health Companies Inc (BHC.TO)?

Bausch Health Companies Inc trades as BHC.TO on the TO exchange (Canada) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-19.

Is BHC.TO in a Closelook index?

Not currently — Bausch Health Companies Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-19.

What is Bausch Health Companies Inc's Closelook composite score?

54 out of 100, with momentum 50, quality 70 and valuation 83 sub-scores, as of 2026-09-19. Scores are Closelook's own research readings, not ratings or investment advice.

Where does BHC.TO trade against its moving averages?

Mixed moving-average stack: Trades -2.7% vs the 50-day and -1.8% vs the 200-day average, 28.5% below the 52-week high and +29.8% off the 52-week low; a golden cross printed 3 sessions ago. Computed from daily closes. As of 2026-09-18 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Bausch Health Companies Inc do?

Bausch Health is a diversified specialty pharmaceutical and medical device company operating through five segments: Salix, International, Solta Medical, Diversified and Bausch + Lomb. It develops and sells products across gastroenterology, hepatology, neurology, dermatology, generics, dentistry, over-the-counter care, aesthetic devices and eye health, across many countries. It is headquartered in Laval, Canada, and was formerly known as Valeant Pharmaceuticals International. Bausch Health is best read against other specialty and generic drugmakers with multiple therapeutic lines, a group that includes Teva Pharmaceutical as a name the market often names alongside it.

Where does Bausch Health Companies Inc sit in the AI build-out?

Bausch Health carries no seat in our index, so it sits within our broader healthcare universe, in the specialty and generic drugmakers sleeve rather than the AI build-out stack. Its business runs on prescription and device sales rather than compute infrastructure, so it stands outside the layers our diary tracks for chip and data-centre demand. Bausch Health holds no seat in our index and carries no score yet, so the diary follows it only through its own chart readings rather than through index quotes.

Does Bausch Health Companies Inc pay a dividend?

No cash distribution shows in Bausch Health Companies Inc’s price series over the last three years. The share count rose 1.9% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for BHC.TO, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Drug Manufacturers - Specialty & Generic, then Healthcare. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.